Sidley Represents Pyxis Oncology in an up to US$282.6 Million Public Offering

Sidley represented Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage biotechnology company developing next-generation therapeutics for difficult-to-treat cancers, in its underwritten public offering of common stock, pre-funded warrants, and accompanying common warrants. The offering is expected to generate approximately US$110 million in gross proceeds, with the potential for up to approximately US$172.6 million in additional gross proceeds if the warrants are exercised in full.

The Sidley team was led by Asher Rubin (Technology and Life Sciences Transactions) and Istvan Hajdu (Capital Markets), and included Henry Dickinson and Eric Carlson (Capital Markets); Torrey Cope and Lauren Limbach (Food, Drug and Medical Device); and Dan Altman and Ryan Kelly (Tax).